ArticleMolecular medicine (Cambridge, Mass.)2021

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.

Ying Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.